Clinical and molecular characterization of early T-cell precursor leukemia: A high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations

Blood Cancer Journal

Volumn 2, Issue 1, 2012, Pages

  Neumann, M ^a   Heesch, S ^a   Gokbuget N ^b   Schwartz, S ^a   Schlee, C ^a   Benlasfer, O ^a   Farhadi Sartangi, N ^a   Thibaut, J ^a   Burmeister, T ^a   Hoelzer, D ^b   Hofmann, W K ^c   Thiel, E ^a   Baldus, C D ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute lymphoblastic leukemia; ETP ALL; FLT3; Molecular characteristics; NOTCH1; T ALL

Indexed keywords

ANTINEOPLASTIC AGENT; BAALC PROTEIN; CD135 ANTIGEN; FBXW7 PROTEIN; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7; NOTCH1 RECEPTOR; PROTEIN; SOMATOMEDIN BINDING PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 1; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HIGH RISK POPULATION; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRE T LYMPHOCYTE; T CELL LEUKEMIA;

EID: 84863966948     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.49     Document Type: Article

References (65)

1. Rothenberg EV, Moore JE, Yui MA. Launching the T-cell-lineage developmental programme. Nat Rev Immunol 2008; 8: 9-21.
2. Tremblay CS, Hoang T, Hoang T. Early T cell differentiation lessons from T-cell acute lymphoblastic leukemia. Prog Mol Biol Transl Sci 2010; 92: 121-156.
3. Bell JJ, Bhandoola A. The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature 2008; 452: 764-767. (Pubitemid 351521083)
4. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147-156.
5. Meijerink JP. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2010; 23: 307-318.
6. Chiaretti S, Foa R. T-cell acute lymphoblastic leukemia. Haematologica 2009; 94: 160-162.
7. Hoelzer D, Thiel E, Arnold R, Beck J, Beelen D, Bornhäuser M et al. Sucessful subtype oriented treatment strategies in adult T-ALL: results of 744 patients treated in three consecutive GMALL studies. Blood 2009; 144: 324.
8. Mullighan CG. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice. Clin Cancer Res 2011; 17: 396-400.
9. Bruggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107: 1116-1123. (Pubitemid 43156313)
10. Baldus CD, Burmeister T, Martus P, Schwartz S, Gökbuget N, Bloomfield CD et al. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 2006; 24: 4714-4720. (Pubitemid 46630935)
11. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998; 92: 1898-1909. (Pubitemid 28446678)
12. Schwartz S, Rieder H, Schlager B, Burmeister T, Fischer L, Thiel E. Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10(-)/CD24(-)/ CD65s(+)/CD15(+) B-cell phenotype. Leukemia 2003; 17: 1589-1595. (Pubitemid 36986961)
13. Baldus CD, Martus P, Burmeister T, Schwartz S, Gökbuget N, Bloomfield CD et al. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 2007; 25: 3739-3745. (Pubitemid 47376607)
14. Heesch S, Goekbuget N, Stroux A, Tanchez JO, Schlee C, Burmeister T et al. Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica 2010; 95: 942-949.
15. Heuser M, Beutel G, Krauter J, Döhner K, von Neuhoff N, Schlegelberger B et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006; 108: 3898-3905. (Pubitemid 44864574)
16. Weng AP, Nam Y, Wolfe MS, Pear WS, Griffin JD, Blacklow SC et al. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 2003; 23: 655-664. (Pubitemid 36050558)
17. Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. Haematologica 2009; 94: 1383-1390.
18. Nowak D, Mossner M, Baldus CD, Hopfer O, Thiel E, Hofmann WK. Mutation analysis of hCDC4 in AML cells identifies a new intronic polymorphism. Int J Med Sci 2006; 3: 148-151. (Pubitemid 44656362)
19. Heesch S, Schlee C, Neumann M, Stroux A, Kühnl A, Schwartz S et al. BAALCassociated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia. Leukemia 2010; 24: 1429-1436.
20. Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060-1067.
21. Grosveld GC. MN1, a novel player in human AML. Blood Cells Mol Dis 2007; 39: 336-339. (Pubitemid 47484474)
22. Malyukova A, Dohda T, von der LN, Akhoondi S, Corcoran M, Heyman M et al. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007; 67: 5611-5616. (Pubitemid 46984990)
23. Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program 2009, 353-361.
24. Mansur MB, Emerenciano M, Splendore A, Brewer L, Hassan R, Pombo-de-Oliveira MS. T-cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements. Leuk Res 2010; 34: 483-486.
25. Kox C, Zimmermann M, Stanulla M, Schrappe M, Ludwig WD, Koehler R. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010; 24: 2005-2013.
26. Clappier E, Collette S, Grardel N, Suarez L, Brunie G, Kaltenbach S et al. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 2010; 24: 2023-2031.
27. Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, Kooi C et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 2010; 24: 2014-2022.
28. Ferrando A. NOTCH mutations as prognostic markers in T-ALL. Leukemia 2010; 24: 2003-2004.
29. Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006; 108: 1151-1157. (Pubitemid 44232009)
30. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542. (Pubitemid 34925124)
31. Xu B, Li L, Tang JH, Zhou SY. Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia. Di Yi Jun Yi Da Xue Xue Bao 2005; 25: 1207-1210.
32. Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 2004; 104: 558-560. (Pubitemid 38900041)
33. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009; 114: 5136-5145.
34. Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009; 46: 64-75.
35. Wood B, Winter S, Dunsmore K, Raetz E, Borowitz M, Devidas M et al. Patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) have high levels of minimal residual disease (MRD) at the end of induction-a Children's Oncology Group (COG) Study. Blood 2009; 114: 9.
36. Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-284.
37. Pui CH, Pei D, Sandlund JT, Ribeiro RC, Rubnitz JE, Raimondi SC et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 371-382.
38. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 532-543.
39. Hoelzer D, Gokbuget N, Ottmann O, Pui CH, Relling MV, Appelbaum FR et al. Acute lymphoblastic leukemia. Hematology. Am Soc Hematol Educ Program 2002, 162-192.
40. Thiel E, Kranz BR, Raghavachar A, Bartram CR, Löffler H, Messerer D et al. Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood 1989; 73: 1247-1258. (Pubitemid 19107430)
41. Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2003; 102: 1613-1618. (Pubitemid 37022550)
42. Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM et al. Differential gene expression patterns and interaction networks in BCR-ABL-positive and negative adult acute lymphoblastic leukemias. J Clin Oncol 2007; 25: 1341-1349. (Pubitemid 46706880)
43. Kuhnl A, Gokbuget N, Stroux A, Burmeister T, Neumann M, Heesch S et al. High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 2010; 115: 3737-3744.
44. Heesch S, Schlee C, Neumann M, Stroux A, Kuehnl A, Schwartz S et al. Gene expression profiling identifies IGFBP-7 as a BAALC co-expressed gene with a functional role in acute leukemia. Blood 2009; 114: 2629.
45. Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A, Verstegen M et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 2011; 19: 484-497.
46. Barragan E, Cervera J, Bolufer P, Ballester S, Martín G, Fernández P et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004; 89: 926-933. (Pubitemid 39049900)
47. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2008; 26: 4595-4602.
48. Tosello V, Mansour MR, Barnes K, Paganin M, Sulis ML, Jenkinson S et al. WT1 mutations in T-ALL. Blood 2009; 114: 1038-1045.
49. Renneville A, Kaltenbach S, Clappier E, Collette S, Micol JB, Nelken B et al. Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies. Leukemia 2010; 24: 476-480.
50. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26: 5429-5435.
51. Chiaretti S, Messina M, Tavolaro S, Zardo G, Elia L, Vitale A et al. Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223. Haematologica 2010; 95: 1114-1121.
52. Weng AP, Ferrando AA, Lee W, Morris IV JP, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271. (Pubitemid 39336870)
53. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006; 6: 347-359.
54. Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2010.
55. Palomero T, Ferrando A. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma 2009; 9(Suppl 3): S205-S210.
56. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996; 183: 2283-2291. (Pubitemid 26158919)
57. Chiang MY, Xu L, Shestova O, Histen G, L'heureux S, Romany C et al. Leukemiaassociated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 2008; 118: 3181-3194.
58. O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH et al. Activating Notch1 mutations in mouse models of T-ALL. Blood 2006; 107: 781-785. (Pubitemid 43076406)
59. Mansour MR, Duke V, Foroni L, Patel B, Allen CG, Ancliff PJ et al. Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin Cancer Res 2007; 13: 6964-6969. (Pubitemid 350276876)
60. Jeannet R, Mastio J, Macias-Garcia A, Oravecz A, Ashworth T, Geimer Le Lay AS et al. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood 2010; 116: 5443-5454.
61. Ashworth TD, Pear WS, Chiang MY, Blacklow SC, Mastio J, Xu L et al. Deletionbased mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood 2010; 116: 5455-5464.
62. Hosoya T, Kuroha T, Moriguchi T, Cummings D, Maillard I, Lim KC et al. GATA-3 is required for early T lineage progenitor development. J Exp Med 2009; 206: 2987-3000.
63. Chi AW, Chavez A, Xu L, Weber BN, Shestova O, Schaffer A et al. Identification of Flt3+CD150- myeloid progenitors in adult mouse bone marrow that harbor T lymphoid developmental potential. Blood 2011; 118: 2723-2732.
64. Scharnhorst V, Wals J, Beverloo HB, Langerak AW, van der Velden VH. Mutation of FLT3 is not a general phenomenon in CD117-positive T-ALL. Leuk Res 2006; 30: 245-246. (Pubitemid 41773349)
65. Sanz M, Burnett A, Lo-Coco F, Lowenberg B. FLT3 inhibition as a targeted therapy for acute myeloid leukemia. Curr Opin Oncol 2009; 21: 594-600.